EUCTR2012-000345-12-NL进行中（未招募）不适用
A phase II study of gefitinib and fulvestrant in patients with advanced, EGFR mutated non-small cell lung cancer pretreated with reversible EGFR tyrosine kinase inhibitors - Gefitinib and fulvestrant in NSCLC
VU Medical Center0 个研究点开始时间: 2012年3月29日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Histologically or cytologically confirmed NSCLC locally advanced and metastatic disease stage IIIB and IV, that have an activating EGFR mutation, progressive on treatment with gefitinib or erlotinib. Patients with unknown mutation status that have exhibited a response to these agents or stable disease for at least 6 months while on treatment with gefitinib or erlotinib are also eligible
- •2.At least one unidimensionally measurable lesion meeting RECIST criteria
- •3.ECOG PS 0-2
- •4.Age > 18 years
- •5.Adequate organ function, including:
- •a.Adequate bone marrow reserve: ANC > 1.5 x 109/L, platelets > 100 x 109/L.
- •b.Hepatic: bilirubin <1.5 x ULN, AP, ALT, AST < 3.0 x ULN
- •AP, ALT, and AST <5 xULN is acceptable if the liver has tumour involvement
- •c.Renal: calculated creatinine clearance > 45 ml/min based on the Cockroft and Gault formula.
- •6.Signed informed consent
- •7.Male and female patients with reproductive potential must use an approved contraceptive method, if appropriate. Female patients with childbearing potential must have a negative serum pregnancy test within 14 days prior to study enrollment.
- •8.Estimated life expectancy >12 weeks.
- •9.Patient compliance and geographical proximity that allow adequate follow up.
- •10.NSCLC with an activating sensitising EGFR TK mutation as determined by using a well-validated and robust methodology.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 48
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Pregnant or lactating women
- •2.Patients who are poor medical risks because of non-malignant disease as well as those with active uncontrolled infection.
- •3.Documented brain metastases unless the patient has completed local therapy for central nervous system metastases and has been off corticosteroids for at least two weeks before enrollment.
- •4.Concomitant treatment with any other experimental drug under investigation.
- •5.Known severe hypersensitivity to gefitinib or any of the excipients of the product.
- •6.Presence of EGFR TK mutation reported to confer resistance to EGFR TKI: i.e., exon 20 point mutation (T790M or S768I EGFR) or exon 20 insertion as determined by using a well-validated and robust methodology.
- •7.Past medical history of interstitial lung disease, drug-induced interstitial disease, radiation pneumonitis which required steroid treatment or any evidence of clinically active interstitial lung disease.
- •8.Concomitant use of known CYP 3A4 inducers such as phenytoin, carbamazepine, rifampicin, barbiturates, or St John's Wort.
- •9.Previous enrolment or treatment in the present study.
研究者
相似试验
撤回
2 期
A phase II study of gefitinib and fulvestrant in patients with advanced EGFR mutated non small cell lung cancer pretreated with reversible EGFR tyrosine kinase inhibitorsadvanced stage non-small cell lung cancermetastatic non-small cell lung cancer1003866610029107NL-OMON37908Vrije Universiteit Medisch Centrum48
已完成
不适用
Gefitinib and fulvestrant in patients with advanced, EGFR mutated NSCLC pretreated with EGFR TKI's.NL-OMON28300VU University Medical Center48
已完成
2 期
Phase II study of gefitinib therapy inserted by chemotherapy as first line treatment for advanced non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutatioon-small-cell lung cancerJPRN-UMIN000001738Thoracic Medical Oncology, National Cancer Center Hospital33
已完成
2 期
Phase II study of gefitinib in untreated advanced non-small cell lung cancer with EGF receptor mutationsnon-small cell lung cancerJPRN-C000000184Hokkaido Lung Cancer Clinical Study Group16
已完成
不适用
A phase II trial of gefitinib in combination with bevacizumab as first line therapy for advanced non-small-cell lung cancer with mutated EGFRnon-small-cell lung cancerJPRN-UMIN000004296Okayama Lung Cancer Study Group42